Literature DB >> 17569757

The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice.

Sara Johnston1, Sharon Andrews, Victor Shen, Felicia Cosman, Robert Lindsay, David W Dempster, Akiko Iida-Klein.   

Abstract

A cyclic PTH regimen is as effective as a daily regimen on bone density gain in humans and in improving bone quality in mice. Our previous murine study evaluated the effects of a cyclic PTH regimen in the absence of a bisphosphonate, whereas our human study addressed the effects of a cyclic PTH regimen in the presence of ongoing alendronate (ALN) treatment. Accordingly, the current study examined the effects of cyclic or daily PTH regimens in combination with ALN on bone quality and bone density in mice. Twenty-week-old, female C57BL/6J mice were treated with the following sc injections (n = 10): 1) vehicle for 5 d/wk (control); 2) ALN (20 microg/kg x d) 3 d/wk (ALN); 3) human PTH(1-34) (40 microg/kg x d) 5 d/wk (daily PTH); 4) daily PTH in addition to ALN (daily PTH plus ALN); 5) PTH 5 d/wk and vehicle 5 d/wk alternating weekly (cyclic PTH); 6) cyclic PTH in addition to ALN (cyclic PTH plus ALN); and 7) PTH and ALN alternating weekly (alt PTH and ALN). Bone mineral density was measured weekly by dual-energy x-ray absorptiometry, and at 7 wk, bone markers, bone structure, and bone strength were evaluated by biochemical assays, peripheral quantitative computed tomography and mechanical testing, respectively. At 7 wk, all treatments significantly increased femoral and vertebral bone mineral density. ALN slightly decreased endosteal circumference, whereas PTH increased periosteal circumference, resulting in significant increases in femoral cortical thickness in all groups. PTH and ALN enhanced bone strength synergistically in the lumbar vertebrae and additively in the femur. Combined therapy, however, had no effects on bone markers. The results show that combinations of ALN and PTH, in both daily and cyclic regimens, produce more beneficial effects than treatment with either agent alone, suggesting that the mechanisms of actions of ALN and PTH on bone quality may be complementary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569757     DOI: 10.1210/en.2007-0229

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface.

Authors:  Y F Li; X D Li; C Y Bao; Q M Chen; H Zhang; J Hu
Journal:  Osteoporos Int       Date:  2013-01-08       Impact factor: 4.507

2.  μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy.

Authors:  Chantal M J de Bakker; Allison R Altman; Wei-Ju Tseng; Mary Beth Tribble; Connie Li; Abhishek Chandra; Ling Qin; X Sherry Liu
Journal:  Bone       Date:  2014-12-30       Impact factor: 4.398

3.  Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.

Authors:  Dominique D Pierroz; Nicolas Bonnet; Paul A Baldock; Michael S Ominsky; Marina Stolina; Paul J Kostenuik; Serge L Ferrari
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

4.  Effect of intermittent PTH(1-34) on human periodontal ligament cells transplanted into immunocompromised mice.

Authors:  Michael Wolf; Stefan Lossdörfer; Nuersailike Abuduwali; Rainer Meyer; Sied Kebir; Werner Götz; Andreas Jäger
Journal:  Tissue Eng Part A       Date:  2012-05-21       Impact factor: 3.845

5.  The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats.

Authors:  Y F Li; C C Zhou; J H Li; E Luo; S S Zhu; G Feng; J Hu
Journal:  Osteoporos Int       Date:  2011-09-03       Impact factor: 4.507

6.  PTH(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology.

Authors:  Christopher M Bartlow; Megan E Oest; Kenneth A Mann; Nicholas D Zimmerman; Bilal B Butt; Timothy A Damron
Journal:  J Orthop Res       Date:  2016-10-03       Impact factor: 3.494

7.  Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation.

Authors:  Glenda J Pettway; Jeffrey A Meganck; Amy J Koh; Evan T Keller; Steven A Goldstein; Laurie K McCauley
Journal:  Bone       Date:  2007-12-15       Impact factor: 4.398

Review 8.  Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives.

Authors:  Chenggui Zhang; Chunli Song
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.